Thursday, July 20, 2023
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines for infectious diseases and cancer in the United States and internationally. The company through its patented Modified Vaccinia Ankara-Virus Like Particle vaccine platform develops various vaccines. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; United States Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; Peking University; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Phase 2 Trial In CLL Has Begun. GeoVax announced that its CM04S1 vaccine has started a Phase 2 investigator-initiated trial (IIT) for protection against COVID-19 in chronic lymphocytic leukemia (CLL) patients. These patients have compromised immune systems and often have poor immune responses to vaccinations. CM04S1 is a bivalent vaccine that stimulates immunity against both the spike protein (S-protein) and the nucleocapsid (N) protein of the SARS-CoV-2 virus. It is currently in a separate Phase 2 trial for immunocompromised patients and in development as a universal booster vaccine.
There Is Still An Unmet Need In COVID-19. Although the COVID-19 pandemic has been declared over, new variants continue to arise throughout the world. Most have been less harmful although highly contagious. Historically, viruses (such as influenza) have had genetic drift over time and mutate to produce new, deadly strains. This is one of the reasons the US government has allocated $5 billion for Project NextGen to continue development efforts for new coronavirus vaccines and treatments.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.